Pharmaceutical Formulation Comprising Lanthanum Compounds

Patent No. EP2792363 (titled "Pharmaceutical Formulation Comprising Lanthanum Compounds") was filed by Shire Biopharmaceuticals Ireland on Aug 26, 2004. The application was issued on Jun 29, 2016.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
NATCO PHARMA	Mar 23, 2017	J A KEMP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Oct 25, 2018
Communication to the parties concerning the termination of the opposition proceedings (proprietor)
Oct 22, 2018
Termination of the opposition proceedings with revocation of patent
Jul 24, 2018
Advice of delivery
Jul 11, 2018
Advice of delivery
Jul 9, 2018
Decision of the Opposition Division and instruction
Jul 9, 2018
Decision revoking the European patent
Jul 9, 2018
Grounds for the decision (Annex) - opposition
Jul 9, 2018
Internal form - Opposition/addressees
Jul 9, 2018
Scanned annex to a communication - opposition procedure
Jun 28, 2018
Transmittal of third party observations to applicant
Jun 22, 2018
Non-patent literature filed by a third party
Jun 22, 2018
Non-patent literature filed by a third party
Jun 22, 2018
Observations by third parties
Jun 22, 2018
Observations by third parties
Jun 22, 2018
Observations by third parties
Jun 22, 2018
Observations by third parties
Jun 22, 2018
Observations by third parties
Jun 8, 2018
Notification concerning the date of oral proceedings
May 25, 2018
Notification concerning the date of oral proceedings
May 24, 2018
(Electronic) Receipt
May 24, 2018
Amended claims with annotations
May 24, 2018
Claims
May 24, 2018
Letter accompanying subsequently filed items
May 24, 2018
Letter regarding the opposition procedure (no time limit)
May 17, 2018
Brief communication - Opposition proceedings
May 17, 2018
Brief communication - Opposition proceedings
May 14, 2018
(Electronic) Receipt
May 14, 2018
Letter accompanying subsequently filed items
May 14, 2018
Withdrawal of an opposition
Nov 15, 2017
(Electronic) Receipt
Nov 15, 2017
Advice of delivery
Nov 15, 2017
Letter accompanying subsequently filed items
Nov 14, 2017
Advice of delivery
Nov 10, 2017
Advice of delivery
Nov 7, 2017
Acknowledgement of a document
Nov 7, 2017
Acknowledgement of a document
Nov 7, 2017
Annex to the communication - opposition
Nov 7, 2017
Information concerning oral proceedings
Nov 7, 2017
Preparation for oral proceedings
Nov 7, 2017
Summons to attend oral proceedings
Nov 7, 2017
Summons to attend oral proceedings
Sep 21, 2017
Brief communication - Opposition proceedings
Sep 18, 2017
(Electronic) Receipt
Sep 18, 2017
Amended claims with annotations
Sep 18, 2017
Claims
Sep 18, 2017
Letter accompanying subsequently filed items
Sep 18, 2017
Reply of the patent proprietor to the notice(s) of opposition
Jul 6, 2017
Communication of amended entries
Jun 6, 2017
Request for change of opponent's representative
May 10, 2017
Communication of a notice of opposition and request to file observations
May 10, 2017
Notice of further oppositions to opponent(s)
Apr 4, 2017
Communication of a notice of opposition - first information to patent proprietor
Mar 23, 2017
(Electronic) Receipt
Mar 23, 2017
Citation in opposition procedure
Mar 23, 2017
Citation in opposition procedure
Mar 23, 2017
Citation in opposition procedure
Mar 23, 2017
Citation in opposition procedure
Mar 23, 2017
Citation in opposition procedure
Mar 23, 2017
Citation in opposition procedure
Mar 23, 2017
Non-patent literature cited during the opposition procedure
Mar 23, 2017
Non-patent literature cited during the opposition procedure
Mar 23, 2017
Non-patent literature cited during the opposition procedure
Mar 23, 2017
Non-patent literature cited during the opposition procedure
Mar 23, 2017
Non-patent literature cited during the opposition procedure
Mar 23, 2017
Non-patent literature cited during the opposition procedure
Mar 23, 2017
Notice of opposition
Mar 23, 2017
Notice of opposition
Mar 23, 2017
Patent document cited during the opposition procedure
Mar 23, 2017
Patent document cited during the opposition procedure
Mar 23, 2017
Patent document cited during the opposition procedure
Mar 23, 2017
Patent document cited during the opposition procedure
Jun 30, 2016
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Jun 2, 2016
Decision to grant a European patent
May 17, 2016
(Electronic) Receipt
May 17, 2016
Filing of the translations of the claims
May 9, 2016
Bibliographic data of the European patent application
May 9, 2016
Communication about intention to grant a European patent
May 9, 2016
Intention to grant (signatures)
May 9, 2016
Text intended for grant (clean copy)
May 9, 2016
Text intended for grant (version for approval)
Apr 15, 2016
Processing of request for correction of text proposed for grant or third party observations (from 01-04-2012)
Mar 24, 2016
(Electronic) Receipt
Mar 24, 2016
Amended description with annotations
Mar 24, 2016
Description
Mar 24, 2016
French translation of claims
Mar 24, 2016
German translation of the claims
Mar 24, 2016
Letter accompanying subsequently filed items
Mar 24, 2016
Request for correction/amendment of the text proposed for grant sent from 01.04.2012
Feb 23, 2016
Submission concerning representation
Nov 25, 2015
Bibliographic data of the European patent application
Nov 25, 2015
Communication about intention to grant a European patent
Nov 25, 2015
Intention to grant (signatures)
Nov 25, 2015
Text intended for grant (clean copy)
Nov 25, 2015
Text intended for grant (version for approval)
Aug 13, 2015
(Electronic) Receipt
Aug 13, 2015
Amended claims with annotations
Aug 13, 2015
Amended description with annotations
Aug 13, 2015
Claims
Aug 13, 2015
Description
Aug 13, 2015
Letter accompanying subsequently filed items
Aug 13, 2015
Reply to communication from the Examining Division
May 6, 2015
Annex to the communication
May 6, 2015
Communication from the Examining Division
Apr 28, 2015
Examination started
Jan 26, 2015
(Electronic) Receipt
Jan 26, 2015
Amended claims filed after receipt of (European) search report
Jan 26, 2015
Amended claims with annotations
Jan 26, 2015
Amendments received before examination
Jan 26, 2015
Letter accompanying subsequently filed items
Oct 29, 2014
Refund of fees
Oct 27, 2014
Reminder period for payment of examination fee/designation fee and correction of deficiencies in Written Opinion/amendment
Sep 24, 2014
Notification of forthcoming publication
Sep 22, 2014
Communication regarding the transmission of the European search report
Sep 22, 2014
European search opinion
Sep 22, 2014
European search report
Sep 17, 2014
Refund of fees
Aug 8, 2014
(Electronic) Receipt
Aug 8, 2014
Claims
Aug 8, 2014
Letter accompanying subsequently filed items
Aug 8, 2014
Matter concerning the application
Jul 4, 2014
Communication to designated inventor
Jul 4, 2014
Communication to designated inventor
Jul 4, 2014
Communication to designated inventor
Jun 10, 2014
Invitation to file claims
May 12, 2014
Abstract
May 12, 2014
Acknowledgement of receipt of electronic submission of the request for grant of a European patent
May 12, 2014
Description
May 12, 2014
Designation of inventor
May 12, 2014
Designation of inventor
May 12, 2014
Designation of inventor
May 12, 2014
Drawings
May 12, 2014
Request for grant of a European patent
Mar 23, 2005
Priority document (electronically transmitted)
Mar 23, 2005
Priority document (electronically transmitted)

EP2792363

SHIRE BIOPHARMACEUTICALS IRELAND

Application Number: EP14167982A
Filing Date: Aug 26, 2004
Status: Revoked; Oct 26, 2018
Publication Date: Jun 29, 2016
External Links: Slate, Register , Google Patents

IP Verse

Pharmaceutical Formulation Comprising Lanthanum Compounds

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP2792363